

Format for submission Unaudited /Audited financial results by companies other than Banks

Statement of Standalone/ Consolidated Unaudited/ Audited Results for the Quarter 30.09.2016						
Particulars	3 Months ended 30.09.2016	Preceding 3 months ended 30.06.16	Corresponding 3 months ended 30.09.2015	Year to date figures current period ended 01.04.2016 to 30.09.2016	Previous year ended 2015-16	
(Refer Notes Below)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)	
1 Income from Operations						
(a) Net sales/income from operation (Net of excise duty)	-	-	-	-	-	
(b) Other operating income	150,000.00	150,000.00	-	300,000.00	600,328.00	
Total income from operations (net)	150,000.00	150,000.00	-	300,000.00	600,328.00	
2 Expenses						
(a) Cost of materials consumed	-	-	-	-	-	
(b) Purchase of stock-in-trade	-	-	-	-	-	
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	-	-	-	-	-	
(d) Employee benefits expense	-	-	-	-	-	
(e) Depreciation and amortisation expense	-	-	-	-	-	
(f) Other expenses (Any item exceeding 10% of the total expenses relating to continuing operations to be shown separately)	140,706.00	108,917.00	108,499.00	249,623.00	486,018.00	
Total expenses	140,706.00	108,917.00	108,499.00	249,623.00	486,018.00	
3 Profit/(Loss) from operations before other income, finance costs and exceptional items (1-2)	9,294.00	41,083.00	(108,499.00)	50,377.00	114,310.00	
4 other income	-	-	-	-	-	
5 Profit/ (Loss) from ordinary activities before finance costs and exceptional (3+ /-4)	9,294.00	41,083.00	(108,499.00)	50,377.00	114,310.00	
6 Finance costs	-	-	-	-	-	
7 Profit / (Loss) from ordinary activities after fiance costs but before exceptional items (5(+/-)6)	9,294.00	41,083.00	(108,499.00)	50,377.00	114,310.00	
8 Exceptional items	-	-	-	-	-	
9 Profit / (Loss) from ordinary activities before tax (7(+/-)8)	9,294.00	41,083.00	(108,499.00)	50,377.00	114,310.00	
10 Tax expense	-	-	-	-	-	
11 Net Profit / (Loss) from ordinary activities after tax (9(+/-)10)	9,294.00	41,083.00	(108,499.00)	50,377.00	114,310.00	
12 Extraordinary items (net of expense Rs. _____ Lakhs)	-	-	-	-	-	
13 Net Profit / (Loss) for the period (11(+/-)12)	9,294.00	41,083.00	(108,499.00)	50,377.00	114,310.00	
14 Share of profit / (Loss) of associates*	-	-	-	-	-	
15 Minority interest*	-	-	-	-	-	
16 Net Profit / (Loss) after taxes, minority interest and share of profit / loss of associates (13(+/-)14(+/-)15)*	9,294.00	41,083.00	(108,499.00)	50,377.00	114,310.00	
17 Paid-up equity share capital (Face Value Rs 10)	37,413,000.00	37,413,000.00	44,545,500.00	37,413,000.00	37,413,000.00	
18 Reserve excluding Revaluation Reserves as per balance sheet of previous accounting year	-	-	1,009,223.00	1,128,021.00	1,128,021.00	
19 i Earnings per share (before extraordinary items) (of Rs. ____/- each) (not annualised):						
(a) Basic						
(b) Diluted						
19 ii Earnings per share (after extraordinary items) (of Rs. ____/- each) (not annualised):						
(a) Basic						
(b) Diluted						

see accompanying note to the financial results



* Applicable in the case of consolidated results

Note: The classification / disclosure of items in the financial results shall be in accordance with the Revised Schedule VI of the Companies Act, 1956.
Further to the above, profit/loss from discontinuing operations, if any, included in the above shall be disclosed with details thereof.

1. The above financial results have been reviewed by the Audit Committee and approved by the Board of Directors at the meeting held on 07.11.2016
2. There were no investors complaints during the quarter ended 30th Sep, 2016
3. Previous years figures has been regroup / rearranged wherever necessary.

Place Hadamtala (Rajkot)
Date: 07.11.2016

PARMAX PHARMA LIMITED

Mr. Aikesh Gopani
Managing Director



Select Information for the Quarter End 30.09.2016

	Particulars	3 months ended 30.09.16	Preceding 3 months ended 30.06.16	Corresponding 3 months ended 30.09.15	Year to date figures for current period ended 01-04-16 to 30- 09-16	Previous year ended 2015-16
A	PARTICULARS OF SHAREHOLDING					
1	Public shareholding					
	Number of shares	2650550	2650550	4010050	2650550	4010050
	Percentage of shareholding	70.85%	70.85%	78.62%	70.85%	78.62%
2	Promoters and Promoter Group Shareholding **					
a)	Pledged / Encumbered					
	Number of shares	Nil	Nil	Nil	Nil	Nil
	Percentage of shares (as a % of the total shareholding of promoter and promoter group)	Nil	Nil	Nil	Nil	Nil
	Percentage of shares (as a % of the total share capital of the company)	Nil	Nil	Nil	Nil	Nil
b)	Non-encumbered					
	Percentage of shares (as a % of the total shareholding of promoter and promoter group)	29.15%	29.15%	21.38%	29.15%	21.38%
	Percentage of shares (as a % of the total share capital of the company)	100%	100%	100%	100%	100%

	Particulars	3 months ended (dd/mm/yyyy)
B	INVESTOR COMPLAINTS	
	Pending at the beginning of the quarter	Nil
	Received during the quarter	Nil
	Disposed of during the quarter	Nil
	Remaining unresolved at the end of the quarter	Nil

Note:

- The above results were reviewed by an Audit Committee and thereafter taken on record by the Board of Directors in their meeting held on 07.11.2016
- There were no investor complaints known to the Company outstanding at the beginning of the quarter.
- Previous period figures have been regrouped wherever necessary.
- Any other notes to be added



BHARAT A. SHAH

B.Com. F.C.A. (DISA)

B. A. SHAH ASSOCIATES

Chartered Accountants

209 Sapphire, 2nd Floor, 21/25 – B, New Jagnath Plot, Rajkot. – 360 001. Ph.: 0281 - 2468261

Auditor's Limited Review Report

On Unaudited Financial Results

To

The Board of Directors,
Parmax Pharma Limited

We have reviewed the accompanying statement of unaudited financial results of **PARMAX PHARMA LIMITED** for the quarter ended on **30th September 2016**. This statement is the responsibility of the Company's Management.

A review of the interim financial information consist principally of applying analytical procedures for the financial data and making enquiries of persons responsible for financial and accounting matters. It is substantially less in scope than audit conducted in accordance with the generally accepted auditing standards, The objective of which is the expression of an opinion regarding the financial statements taken as a whole. Accordingly we do not express such an opinion. Further our review was mainly in regards to the figures of quarter ended 30th June 2016

During our review we have noticed that:

There are small differences between amounts as per published results and corresponding figured as per the accounts (which are however within tile allowed limit of 10% or Rs. 10 lacs, whichever is higher)

Except this nothing has come to our notice that causes us to believe that the accompanying statements of unaudited financial results have not disclosed the information required to be disclosed in terms of clause 41 of the Listing Agreement including the manner in which it is to be disclosed or that it contain any material misstatement.

For B A SHAH ASSOCIATES

Chartered Accountants

FRN.: 109493W

Bharat A Shah

BHARAT SHAH

PROPRIETOR

M. NO.034222



Date: 20.10.2016

Place: Rajkot

Clause 41 of the Listing Agreement For companies (Other than Banks)

	Stadalone / Consolidated Statement of Assets and Liabilities Particulars	As at 30-09-2016	As at 31-03-2016
A	EQUITY AND LIABILITIES		
	1 Shareholder's funds		
	(a) Share capital	44,511,500.00	44,511,500.00
	(b) Reserves and surplus	1,313,397.00	1,128,021.00
	(c) Money received against share warants	-	-
	Sub- total - Shareholder's funds	45,824,897.00	45,639,521.00
	2 Share application money pending allotment	-	-
	3 Minority interest*	-	-
	4 Non-current liabilities		
	(a) Long-term borrowings	7,749,177.00	4,649,177.00
	(b) Deferred tax liabilities (net)	-	-
	© Other long-term liabilities	-	-
	(d) Long-term provisions	-	-
	Sub-total-Non-current liabilities	7,749,177.00	4,649,177.00
	5 Current liabilities		
	(a) Short-term borrowings	-	-
	(b) Trade payables	87,560.00	86,249.00
	(c) Other current liabilities	34,000.00	34,000.00
	(d) Short-term provisions	642,300.00	352,636.00
	Sub-total- Current liabilities	763,860.00	472,885.00
	TOTAL - EQUITY AND LIABILITIES	54,337,934.00	50,761,583.00
B	ASSETS		
	1 Non-current assets		
	(a) Fixed assets	25,331,120.00	25,331,120.00
	(b) Goodwill on consolidation*	-	-
	(c) Non-current investments	6,000.00	6,000.00
	(d) Deferred tax assets (net)	-	-
	(e) Long-term loans and advances	750,899.00	734,400.00
	(f) Other non-current assets	11,974,466.00	8,524,466.00
	Sub-total-Non-current assets	38,062,485.00	34,595,986.00
	2 Current assets		
	(a) Current investments	-	-
	(b) Inventories	-	-
	(c) Trade receivables	1,069,682.00	937,360.00
	(d) Cash and cash equivalents	2,790,402.00	3,066,663.00
	(e) Short-term loans and advances	12,293,365.00	12,161,574.00
	(f) Other current assets	-	-
	Sub-total-Current assets	16,153,449.00	16,165,597.00
	TOTAL - ASSETS	54,215,934.00	50,761,583.00

* Applicable in the case of consolidated statement of financial position

